{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:22:40Z","timestamp":1784352160270,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Fundamental Research Funds for the Central Universities South-Central Minzu University","award":["CZZ23009"],"award-info":[{"award-number":["CZZ23009"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["82074081"],"award-info":[{"award-number":["82074081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["82374104"],"award-info":[{"award-number":["82374104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Knowledge Innovation Program of Wuhan-Basic Research","award":["2022020801010404"],"award-info":[{"award-number":["2022020801010404"]}]},{"name":"Department of Cardiology, Union Hospital, Tongji Medical University, Huazhong University of Science and Technology","award":["82170326"],"award-info":[{"award-number":["82170326"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10067-024-06933-4","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T14:01:35Z","timestamp":1710597695000},"page":"1745-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Fan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-3033","authenticated-orcid":false,"given":"Lvyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"1","key":"6933_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.33315","volume":"64","author":"MA McAdams DeMarco","year":"2012","unstructured":"McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A et al (2012) Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 64(1):121\u2013129","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6933_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L (2018) Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 40(1):289\u2013297","journal-title":"Ren Fail"},{"issue":"3","key":"6933_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321\u2013325","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6933_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 72(6):879\u2013895","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"6933_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6933_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"VF Azevedo","year":"2019","unstructured":"Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha CastelarPinheiro G, Dos Santos Paiva E (2019) Benzbromarone in the treatment of gout. Adv Rheumatol 59(1):37","journal-title":"Adv Rheumatol"},{"issue":"4","key":"6933_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40265-015-0360-7","volume":"75","author":"JE Frampton","year":"2015","unstructured":"Frampton JE (2015) Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs 75(4):427\u2013438","journal-title":"Drugs"},{"key":"6933_CR8","doi-asserted-by":"publisher","first-page":"36092","DOI":"10.1155\/2007\/36092","volume":"2007","author":"C Kunishima","year":"2007","unstructured":"Kunishima C, Inoue I, Oikawa T, Nakajima H, Komoda T, Katayama S (2007) Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res 2007:36092","journal-title":"PPAR Res"},{"key":"6933_CR9","first-page":"Cd006077","volume":"10","author":"R Seth","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, Bombardier C (2014) Edwards CJ (2014) Allopurinol for chronic gout. Cochrane Database Syst Rev 10:Cd006077","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"6933_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0168-8278(00)80263-9","volume":"32","author":"H Wagayama","year":"2000","unstructured":"Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K et al (2000) Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 32(5):874","journal-title":"J Hepatol"},{"issue":"4","key":"6933_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.20634","volume":"41","author":"P Kaufmann","year":"2005","unstructured":"Kaufmann P, T\u00f6r\u00f6k M, H\u00e4nni A, Roberts P, Gasser R, Kr\u00e4henb\u00fchl S (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41(4):925\u2013935","journal-title":"Hepatology"},{"issue":"2","key":"6933_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10067-020-05272-4","volume":"40","author":"M Fan","year":"2021","unstructured":"Fan M, Liu J, Zhao B, Wu X, Li X, Gu J et al (2021) Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol 40(2):683\u2013692","journal-title":"Clin Rheumatol"},{"issue":"6","key":"6933_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10157-018-1586-y","volume":"22","author":"H Yu","year":"2018","unstructured":"Yu H, Liu X, Song Y, Cheng J, Bao H, Qin L et al (2018) Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol 22(6):1324\u20131330","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"6933_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1536\/ihj.20-114","volume":"61","author":"T Nakata","year":"2020","unstructured":"Nakata T, Ikeda S, Koga S, Yonekura T, Tsuneto A, Doi Y et al (2020) Randomized, open-label, cross-over comparison of the effects of benzbromarone and febuxostat on endothelial function in patients with hyperuricemia. Int Heart J 61(5):984\u201392","journal-title":"Int Heart J"},{"issue":"12","key":"6933_CR15","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.42266","volume":"74","author":"F Yan","year":"2022","unstructured":"Yan F, Xue X, Lu J, Dalbeth N, Qi H, Yu Q et al (2022) Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis Rheumatol 74(12):2015\u20132023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"6933_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12882-022-02850-3","volume":"23","author":"T Sapankaew","year":"2022","unstructured":"Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P et al (2022) Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol 23(1):223","journal-title":"BMC Nephrol"},{"issue":"3","key":"6933_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5414\/CP204097","volume":"60","author":"YH Lee","year":"2022","unstructured":"Lee YH, Song GG (2022) Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: a network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther 60(3):159\u2013166","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"6933_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/art.42055","volume":"74","author":"N Dalbeth","year":"2022","unstructured":"Dalbeth N, Doyle AJ, Billington K, Gamble GD, Tan P, Latto K et al (2022) Intensive serum urate lowering with oral urate-lowering therapy for erosive gout: a randomized double-blind controlled trial. Arthritis Rheumatol 74(6):1059\u20131069","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"6933_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/14656566.2015.997213","volume":"16","author":"PC Robinson","year":"2015","unstructured":"Robinson PC, Dalbeth N (2015) Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother 16(4):533\u2013546","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"6933_CR20","first-page":"1620","volume":"33","author":"HW Chou","year":"2018","unstructured":"Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC et al (2018) Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant 33(9):1620\u20131627","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"6933_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"N Liang","year":"2019","unstructured":"Liang N, Sun M, Sun R, Xu T, Cui L, Wang C et al (2019) Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther 21(1):200","journal-title":"Arthritis Res Ther"},{"key":"6933_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"9","key":"6933_CR23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cjca.2020.11.010","volume":"37","author":"PC Austin","year":"2021","unstructured":"Austin PC, White IR, Lee DS, van Buuren S (2021) Missing data in clinical research: a tutorial on multiple imputation. Can J Cardiol 37(9):1322\u20131331","journal-title":"Can J Cardiol"},{"key":"6933_CR24","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2011)","author":"G Wells","year":"2011","unstructured":"Wells G, Shea B, O\u2019Connell D, Robertson J, Peterson J, Welch V et al (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2011). Ottawa Hospital Research Institute, Ottawa"},{"key":"6933_CR25","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A (2011) Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). OCEBM Web site. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence"},{"issue":"6","key":"6933_CR26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 27(6):1785\u20131805","journal-title":"Stat Methods Med Res"},{"key":"6933_CR27","doi-asserted-by":"publisher","unstructured":"Kim SR, Kim K, Lee SA, Kwon SO, Lee JK, Keum N et al (2019) Effect of red, processed, and white meat consumption on the risk of gastric cancer: an overall and dose-response meta-analysis. Nutrients 11(4):826.\u00a0https:\/\/doi.org\/10.3390\/nu11040826. PMID: 30979076; PMCID: PMC65","DOI":"10.3390\/nu11040826"},{"issue":"3","key":"6933_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/hr.2016.139","volume":"40","author":"Y Ohta","year":"2017","unstructured":"Ohta Y, Ishizuka A, Arima H, Hayashi S, Iwashima Y, Kishida M et al (2017) Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertens Res 40(3):259\u2013263","journal-title":"Hypertens Res"},{"key":"6933_CR29","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10(10): Ed000142","DOI":"10.1002\/14651858.ED000142"},{"issue":"8","key":"6933_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/1756-185X.13652","volume":"22","author":"J Wu","year":"2019","unstructured":"Wu J, Zhang YP, Qu Y, Jie LG, Deng JX, Yu QH (2019) Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Int J Rheum Dis 22(8):1445\u20131451","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"6933_CR31","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s10067-022-06110-5","volume":"41","author":"D Liu","year":"2022","unstructured":"Liu D, Zhou B, Li Z, Zhang Z, Dai X, Ji Z et al (2022) Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. Clin Rheumatol 41(7):2121\u20132128","journal-title":"Clin Rheumatol"},{"issue":"2","key":"6933_CR32","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1002\/hsr2.563","volume":"5","author":"M Nishino","year":"2022","unstructured":"Nishino M, Egami Y, Nakamura H, Ukita K, Kawamura A, Matsuhiro Y et al (2022) Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study. Health Sci Rep 5(2):e563","journal-title":"Health Sci Rep"},{"issue":"1","key":"6933_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R (2010) Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6(1):30\u201338","journal-title":"Nat Rev Rheumatol"},{"issue":"10287","key":"6933_CR34","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout Lancet 397(10287):1843\u20131855","journal-title":"Gout Lancet"},{"issue":"10055","key":"6933_CR35","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK (2016) Gout Lancet 388(10055):2039\u20132052","journal-title":"Gout Lancet"},{"issue":"Suppl 2","key":"6933_CR36","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz F (2009) Treating to target: a strategy to cure gout. Rheumatol (Oxford) 48(Suppl 2):ii9\u2013ii14","journal-title":"Rheumatol (Oxford)"},{"key":"6933_CR37","doi-asserted-by":"publisher","first-page":"890305","DOI":"10.3389\/fendo.2022.890305","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Wang Y, Ouyang S, Li M, Liu R, Zhang Y et al (2022) Association between serum uric acid level and carotid atherosclerosis and metabolic syndrome in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 13:890305","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"6933_CR38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","volume":"5","author":"M Banach","year":"2020","unstructured":"Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ et al (2020) Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol 5(10):1124\u20131135","journal-title":"JAMA Cardiol"},{"issue":"1","key":"6933_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12872-019-1026-2","volume":"19","author":"N Ali","year":"2019","unstructured":"Ali N, Rahman S, Islam S, Haque T, Molla NH, Sumon AH et al (2019) The relationship between serum uric acid and lipid profile in Bangladeshi adults. BMC Cardiovasc Disord 19(1):42","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06933-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T05:13:43Z","timestamp":1713158023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06933-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6933"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06933-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}